I am an Associate Director of the NYU Cancer Institute, Director of Translational Cancer Research, and Co-director of the Breast Cancer Research Program at NYU School of Medicine. Our research is directed to three major areas: (1) the molecular and genetic understanding of advanced breast cancers and the development of new treatment strategies and therapeutics for advanced breast cancers, focusing particularly on the role of protein synthesis and mTOR kinase regulation; (2) the molecular understanding of gene regulation by ionizing radiation, particularly its ability to regulate protein synthesis and use of this knowledge for development of new cancer treatment strategies; and (3) regulation of the inflammatory response by targeted rapid degradation of inflammatory cytokine mRNAs, and the connection to cancer development and progression.
Albert B. Sabin Professor of Microbiology and Molecular Pathogenesis, Department of Microbiology
Professor, Department of Radiation Oncology
Associate Dean for Therapeutics Alliances
Fellowship, SUNY Stony Brook/Princeton University, Virology-Virus-cell Interactions
PhD from Mount Sinai School of Medicine
Proceedings of the National Academy of Sciences of the United States of America (PNAS). 2017 Mar 7; 114(12):3186-3191
Translational control pathways form a molecular hub that regulates tamoxifen resistance in ER plus breast cancer [Meeting Abstract]
Cancer research. 2017 MAR; 77:?-?
Molecular & cellular biology. 2017 Feb 15; 37(5):?-?
Cancer research. 2017 FEB; 77:?-?
Molecular cell. 2016 Nov 03; 64(3):507-519
MTOR inhibitors preserve fertility in a murine model: A novel pharmacologic approach to fertility preservation during gonadotoxic chemotherapy [Meeting Abstract]
Fertility & sterility. 2016 Sep; Conference:(ASRM):e2-e3
Cell reports. 2016 Aug 02; 16(5):1379-1390
Cancer research. 2016 Aug 01; 76(15):4394-4405